Research Article
Detection of Bone Metastases by 68Ga-DOTA-SSAs and 18F-FDG PET/CT: A Two-Center Head-to-Head Study of Gastroenteropancreatic Neuroendocrine Neoplasms
Table 1
Patient characteristics (n = 74).
| Basics | Total | G1 + G2 | NET G3 | NEC | P |
| N (%) | 74 | 50 | 12 | 12 | | Age at image (mean ± SD) | 55.93 ± 11.025 | 55.66 ± 10.817 | 51.58 ± 8.028 | 61.42 ± 12.930 | 0.086 | Sex, M/F (%) | 47/27 (63.51/36.49) | 32/18 (64.00/36.00) | 8/4 (66.67/33.33) | 7/5 (58.33/41.67) | 0.905 |
| Primary sites (n, %) | Stomach | 6 (8.11) | 3 (6) | 1 (8.33) | 2 (16.67) | 0.546 | Intestine | 34 (45.95) | 28 (56)a | 4 (33.33)b | 2 (16.67)c | 0.028 | Pancreas | 26 (35.14) | 17 (34) | 4 (33.33) | 5 (41.67) | 0.933 | Esophagus | 3 (4.05) | 1 (2) | | 2 (16.67) | 0.133 | Biliary tract | 2 (2.70) | | 1 (8.33) | 1 (8.33) | 0.102 | Unknown primary origin | 3 (4.05) | 1 (2) | 2 (16.67) | | 0.133 |
| Other extra-osseous metastases (n, %) | Liver metastases | 69 (93.24) | 48 (96) | 11 (91.67) | 10 (83.33) | 0.482 | Lymph node metastases | 50 (67.57) | 36 (72) | 5 (41.67) | 9 (75) | 0.134 |
| Symptoms | 15 (20.27) | 7 (14) | 3 (25) | 5 (41.67) | 0.073 |
| CT findings (n, %) | Osteogenesis | 41 (55.41) | 34 (68)a | 5 (41.67)b | 2 (16.67)c | 0.003 | Osteolysis | 18 (24.32) | 9 (18) | 5 (4.05) | 4 (33.33) | 0.245 | No change | 15 (20.27) | 7 (14)b | 2 (16.67)b | 6 (50)a | 0.026 |
|
|
CT, computed tomography; M/F, male/female; a,b, and c (where a>b>c) mark statistically significant differences between each group.
|